A Phase II Study of Lenalidomide as Maintenance Therapy for Plasma Cell Myeloma

Full Title

Lenalidomide Maintenance in Plasma Cell Myeloma


Very small numbers of multiple myeloma cells can remain in the body after initial therapy. Such “minimal residual disease” increases a person’s risk of experiencing a recurrence of their myeloma. In this study, researchers are assessing the safety and effectiveness of long-term (maintenance) therapy with lenalidomide in patients with no detectable evidence of myeloma after treatment. It is hoped that long-term lenalidomide treatment can delay the time for any remaining myeloma cells to start growing, and can improve survival.

Lenalidomide is already approved for the initial treatment of multiple myeloma when given with dexamethasone; its use in this study is considered investigational. It is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have had induction or re-induction therapy for plasma cell myeloma and show no detectable signs of the cancer.
  • Patients whose myeloma did not previously respond to lenalidomide may not participate.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Ola Landgren at 212-639-5153.